The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs
DI Bernstein, N Farley, FJ Bravo, J Earwood, M McNeal… - Vaccine, 2010 - Elsevier
DI Bernstein, N Farley, FJ Bravo, J Earwood, M McNeal, J Fairman, R Cardin
Vaccine, 2010•ElsevierHerpes simplex virus (HSV) infections are common but there is no vaccine available. We
evaluated cationic liposome–DNA complexes (CLDC) as an adjuvant for an HSV gD2
vaccine and compared it to an MPL/Alum adjuvant in a guinea pig model of genital herpes.
The addition of CLDC to the gD2 vaccine significantly decreased acute and recurrent
disease and most importantly the number of days with recurrent virus shedding compared to
gD2 alone. Reductions in these outcomes were also detected when gD2+ CLDC was …
evaluated cationic liposome–DNA complexes (CLDC) as an adjuvant for an HSV gD2
vaccine and compared it to an MPL/Alum adjuvant in a guinea pig model of genital herpes.
The addition of CLDC to the gD2 vaccine significantly decreased acute and recurrent
disease and most importantly the number of days with recurrent virus shedding compared to
gD2 alone. Reductions in these outcomes were also detected when gD2+ CLDC was …
Herpes simplex virus (HSV) infections are common but there is no vaccine available. We evaluated cationic liposome–DNA complexes (CLDC) as an adjuvant for an HSV gD2 vaccine and compared it to an MPL/Alum adjuvant in a guinea pig model of genital herpes. The addition of CLDC to the gD2 vaccine significantly decreased acute and recurrent disease and most importantly the number of days with recurrent virus shedding compared to gD2 alone. Reductions in these outcomes were also detected when gD2+CLDC was compared to gD2+MPL/Alum. When the vaccine and adjuvants were evaluated as therapeutic vaccines, they were ineffective. CLDC enhanced protection compared to MPL/Alum and is the first vaccine to reduce recurrent virus shedding, a key to decreasing the spread of HSV-2.
Elsevier